China Pharma Holdings (CPHI) Finished Goods (2017 - 2024)

China Pharma Holdings' Finished Goods history runs 8 years deep, the most recent figure standing at $1.3 million for Q3 2024.

• Quarterly Finished Goods rose 6.83% year-over-year to $1.3 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.3 million (up 6.83% YoY) and the FY2023 annual result came in at $1.5 million, up 166.73% from the prior year.
• Finished Goods was $1.3 million for Q3 2024 at China Pharma Holdings, down from $1.5 million in the prior quarter.
• Across five years, Finished Goods topped out at $1.7 million in Q1 2024 and bottomed at $551000.0 in Q4 2021.
• A 5-year average of $1.2 million and a median of $1.3 million in 2022 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2021 — Finished Goods sank 46.0% — and 2023, when it soared 166.73%.
• China Pharma Holdings' Finished Goods stood at $960375.0 in 2020, then plunged by 42.63% to $551000.0 in 2021, then changed by 0.0% to $551000.0 in 2022, then soared by 166.73% to $1.5 million in 2023, then declined by 11.91% to $1.3 million in 2024.
• Business Quant data shows CPHI's Finished Goods at $1.3 million in Q3 2024, $1.5 million in Q2 2024, and $1.7 million in Q1 2024.